Solvay Pharmaceuticals S.A. plans the offer period for Innogenetics from August 12 to September 5, 2008

Solvay Pharmaceuticals S.A., a subsidiary of Solvay, the chemical and pharmaceutical group, today announced that it plans the offer period to acquire Innogenetics N.V., a Belgian-based biotechnological company, from August 12 to September 5, pending approval of the takeover prospectus by Belgium’s Banking, Finance and Insurance Commission (CBFA).